Product Information
CLORAZEPATE 15 MG TABLET is a generic product labeled by Aurolife Pharma LLC, priced at $0.8080 per EA under NDC 13107032101. Its NADAC has been published 240 times since Mar 2, 2022.
FDA first approved this application on Jul 17, 1987. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
15 mg/1
Manufacturer
Aurolife Pharma LLCNDC
13107032101
Classification
Generic
Dosage Form
TABLET
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CLORAZEPATE DIPOTASSIUMApproval Type
Generic (ANDA)
FDA Application
ANDA071858FDA Approved
7/17/1987
TE Code
AB
On Market Since
7/17/1987
Pharmacological Classes
Price Statistics
The NADAC for CLORAZEPATE 15 MG TABLET has been published 240 times since Mar 2, 2022, and over the history we have for it it has declined 71.7%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8080 per EA |
|---|---|
| All-time high | $3.1030 (Jul 13, 2022) |
| All-time low | $0.6724 (Jun 19, 2024) |
| 52-week high | $1.7543 |
| 52-week low | $0.8080 |
| Median price | $1.3881 |
| Average price | $1.6207 |
| Largest weekly change | +94.5% (Mar 20, 2024) |
| Weeks tracked | 240 |
| Tracking since | Mar 2, 2022 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CLORAZEPATE DIPOTASSIUM market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Aurolife Pharma LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CLORAZEPATE DIPOTASSIUM market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Benzodiazepine class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CLORAZEPATE 15 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for CLORAZEPATE 15 MG TABLET, manufactured by Aurolife Pharma LLC, is $0.8080 per EA (NDC 13107032101), effective Sep 30, 2026.
How has the price of CLORAZEPATE 15 MG TABLET changed over time?
Over the history we have for it, the NADAC for CLORAZEPATE 15 MG TABLET has declined 71.7%. It has been tracked across 240 weekly CMS publications since Mar 2, 2022.
What are the highest and lowest recorded NADAC prices for CLORAZEPATE 15 MG TABLET?
Since Mar 2, 2022, the NADAC for CLORAZEPATE 15 MG TABLET has ranged from a low of $0.6724 (Jun 19, 2024) to a high of $3.1030 (Jul 13, 2022), with a median of $1.3881 per EA.
Are there cheaper alternatives to CLORAZEPATE 15 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of CLORAZEPATE 15 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CLORAZEPATE 15 MG TABLET?
CLORAZEPATE 15 MG TABLET (NDC 13107032101) is labeled by Aurolife Pharma LLC, and CMS classifies it as a generic product.